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Poxviruses and adenovirusesThe global vaccine market is diverse while facing a plethora of novel developments. Genetic modification
(GM) techniques facilitate the design of ’smarter’ vaccines. For many of the major infectious diseases of
humans, like AIDS and malaria, but also for most human neoplastic disorders, still no vaccines are avail-
able. It may be speculated that novel GM technologies will significantly contribute to their development.
While a promising number of studies is conducted on GM vaccines and GM vaccine technologies, the con-
tribution of GM technology to newly introduced vaccines on the market is disappointingly limited.
In this study, the field of vector-based GM vaccines is explored. Data on currently available, actually
applied, and newly developed vectors is retrieved from various sources, synthesised and analysed, in
order to provide an overview on the use of vector-based technology in the field of GM vaccine develop-
ment. While still there are only two vector-based vaccines on the human vaccine market, there is ample
activity in the fields of patenting, preclinical research, and different stages of clinical research. Results of
this study revealed that vector-based vaccines comprise a significant part of all GM vaccines in the pipe-
line. This study further highlights that poxviruses and adenoviruses are among the most prominent vec-
tors in GM vaccine development.
After the approval of the first vectored human vaccine, based on a flavivirus vector, vaccine vector tech-
nology, especially based on poxviruses and adenoviruses, holds great promise for future vaccine develop-
ment. It may lead to cheaper methods for the production of safe vaccines against diseases for which no or
less perfect vaccines exist today, thus catering for an unmet medical need. After the introduction of
Jenner’s vaccinia virus as the first vaccine more than two centuries ago, which eventually led to the recent
eradication of smallpox, this and other viruses may now be the basis for constructing vectors that may
help us control other major scourges of mankind.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ever since the discovery by Edward Jenner, more than two cen-
turies ago, that vaccinia virus could be used to protect people from
variola, vaccines have been of utmost importance in fighting infec-
tious diseases [1], as they are the most cost effective tools for the
prevention of infectious diseases. To date several types of vaccines
are available, including live-attenuated, inactivated, subunit or
split, toxoid, conjugate, DNA, and recombinant vectored vaccines
[2]. While conventional vaccines, like live-attenuated or inacti-
vated wild-type, have successfully protected vaccinees from vari-
ous infectious diseases over the years, they are not available for
most infectious diseases and for those who cannot afford them.Conventional vaccine production methods, which predominantly
use viruses and bacteria or their products, produced with classical
production methods, are labour intensive, expensive, and time
consuming, while some of the desired antigens cannot be produced
in this way [3]. Furthermore, highly virulent pathogens can only be
produced under expensive special safety conditions, while attenu-
ated agents may have a tendency of reverting to their pathogenic
form and can usually only be used in fully competent individuals
[4].
To overcome the challenges of traditional vaccine production,
the development and use of novel generations of vaccines, like
those based on GM technologies, are being considered more and
more frequently. The advent of these novel technologies may also
be expected to create opportunities for the development of vacci-
nes targeting new indications and/or application fields. Since there
are many major indications for which no or only unsatisfactory
vaccines are available, like AIDS, malaria, and tuberculosis, the
exploitation of novel technologies, like the use of vector-based vac-
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may eventually allow us to fill the gap of this unmet medical need.
To date several vaccines for humans, based on GM technologies
have been licensed (for review see e.g. [5–8]) and a lot of candi-
dates are in the pipeline.
An interesting approach for vaccine development based on GM
technology is the use of vectors, which carry selected genes encod-
ing antigens that induce protective immunity. They can either be
used as vaccines proper, or for the production of antigens that
are incorporated in vaccines. The present paper only deals with
vectors that are actually used as vaccines and not just for the pro-
duction of immunogens. Vectors can be classified in three different
categories: viral, bacterial, and plasmid [9]. Vectors can either be
fully replicative or only cause abortive infection, still allowing
the expression of the desired immunogens. They can be adminis-
tered either parenterally or via mucosal membranes [10]. A major
advantage of vector-based GM technology, is that the immunogens
of interest are de novo synthesized, thus not only allowing for the
induction of antibody and T helper cell mediated immunity, but
also for the induction of protective cytotoxic T cell responses, mim-
icking a natural immune response against the immunogen. This
balanced immune response opens pathways that were previously
inaccessible with traditional vaccine technology using ‘non-live’
immunogens. Especially the induction of CD8+ CTL responses
may be of particular interest for vaccines against certain virus
infections and cancers [11]. Our previous study provides additional
insights regarding the strengths, weaknesses, opportunities, and
threats of such technology [12].
In the present study, the potential of vector-based vaccines is
evaluated. Data obtained from literature, granted patents, and dif-
ferent stage clinical trials are synthesised and analysed in the light
of data from currently registered vaccines providing an overview of
the potential of currently used and newly generated vectors in the
field of vaccine development. The data suggest that vector-based
vaccines may offer a cost-effective alternative for the production
of safe vaccines against diseases for which no or less perfect vacci-
nes exist today, thus catering for a huge unmet medical need.2. Methodology
The methods applied in this study have been split in four differ-
ent stages: evaluation of literature, patents, clinical trials, and reg-
istered GM and non-GM vaccines. Each stage was individually
examined in detail and the complete data set was compiled. These
stages were decided upon in order to provide a complete overview
of the genetically modified (GM) vector-based vaccine pipeline and
market.Table 1
Results of literature search.
Database Hits Hits after deduplication
Embase.com 945 940
Medline (OvidSP) 364 97
Web-of-science 323 123
PubMed publisher 8 4
Cochrane DARE 7 2
Google scholar 100 79
Total initial search 1756 1245
Total set after applying restrictions 87
Additional vector search results 18
Final set used for detailed analysis 382.1. Literature research
To map the early research stage of emerging vectors, a literature
search was performed on available candidate vector vaccine stud-
ies. Data was collected on various types of GM vectors and their
properties, as mentioned in both research publications and
reviews. The search was conducted using a combination of Embase,
Medline, Web-of-science, Pubmed, Cochrane, and Google Scholar.
Medical Subject Headings (MeSH) and Boolean Operators were uti-
lised in order to develop a basis for the syntax. The search was
restricted to publications/translations in English. This syntax and
the search results were analysed by an independent biomedical
information specialist from Erasmus Medical Centre medical
library. Additional information on the search terms for different
search engines can be found in the supporting information (S1).
A total of 1756 hits were obtained [13]. 511 duplicates were
removed, resulting in 1245 publications. Restrictions for furtheranalysis included articles not describing vaccines or vaccine tech-
nologies, and articles not describing novel vaccine technologies.
Publications were restricted to those published in the period
2009–2014. The total set contained 87 review articles on GM
vaccines.
In order to retrieve more papers on vector-based GM vaccine
candidates, an additional search was performed on Pubmed includ-
ing relevant search terms ‘‘vaccine”, ‘‘vector” and ‘‘GM”. Reviews
were retrieved adding the search term ‘‘review” to the previously
mentioned terms or by searching for reviews only. Papers dating
from the period 1998 to 2014 were collected and 18 new results
were added to the previous 87 (Table 1).
A total of 38 publications, specifically on the topic of vector-
based vaccines, were selected from this pool and analysed in detail.
The clinical studies and reviews evaluated are shown in Table 2,
and the results of this literature study can be found in Table 6.2.2. Search for patents
Patents have multiple technology classifications based on their
claims, and since they are classified in technological classes,
patents related to GM vaccines were collected into a database.
Patent data concerning GM vaccines was retrieved from Espacenet,
which provides access to over 90 million patent documents world-
wide [14]. Search terms used were ‘‘Medicinal preparations contain-
ing antigens or antibodies”, ‘‘Medicinal preparations containing
genetic material which is inserted into cells of the living body to treat
genetic diseases; Gene therapy” and ‘‘Mutation or genetic engineering;
DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or
their isolation, preparation or purification; Use of hosts therefore”, in
combination with search words vaccin⁄ (Boolean operator), and
genetic⁄ OR modif⁄, respectively. The results were deduplicated
based on the priority numbers. The syntax and search results were
analysed by a patent specialist from the Netherlands Enterprise
Agency (RVO) [15], a governmental institution in the department
of Economic Affairs. A total number of 40.308 unique patents were
found and an original database was created, including all classes
and subclasses.
As patent information in the patent database is condensed into
Cooperative Patent Classification (CPC) codes, the previous search
was repeated, combining the previous search with CPC codes for
vectors and search term vaccine⁄. A total of 96 unique CPC codes
were used, resulting in 32.738 vector-based vaccine patent docu-
ments. As CPC codes describe the classification in each technical
area on various levels, the definitions of the CPC codes used were
retrieved from Espacenet, and a comprehensive table was created
including the CPC codes, their definitions, and the number patents
containing this specific code. All search terms can be found in
Table 3. The results are illustrated in Fig. 1 and a complete over-
view of these CPC codes and their description can be found in
the supporting information (S2). It should be noted that the
Table 2
List of clinical studies and reviews evaluated.
Altenburg et al. [48] Nébié et al. [44]
Arroyo et al. [34] Nieto and Salvetti [30]
Babu Appaiahgari and Vrati [33] Ondondo [52]
Banchereau and Steinman [36] Pandey et al. [27]
Bermúdez-Humarán et al. [58] Paris et al. [43]
Bråve et al. [28] Ploquin et al. [31]
Chin’ombe et al. [60] Rimmelzwaan and Sutter [55]
Choi and Chang [35] Robertson [51]
Cottingham et al. [56] Rollier et al. [11]
Croyle et al. [41] Saxena et al. [39]
Dicks et al. [40] Smith et al. (2011)
Dung et al. (2012) Tatsis and Ertl [37]
Ewer et al. [45] Tripp and Tompkins [47]
Gómez et al. [49] Ulmer et al. [3]
Hessel et al. [54] Ura et al. [32]
Kreijtz et al. [26] Verheust et al. [53]
Lundstrom [46] Weaver and Barry [42]
Mooney and Tompkins [38] Williams et al. [29]
Myhr et al. [50] Youngjoo et al. (2013)
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used to reproduce search terms for the vector search. Because of
this iterative method, a complete dataset was collected.2.3. Search for clinical trials
Clinical trials data (phase 1, 2, and 3) was gathered from the
World Health Organisation International Clinical Trials Registry
Platform, which currently lists 191,038 studies in 190 countries
(data retrieved: May 29th, 2015 [16]). Search terms applied can
be found in Table 4. The results were deduplicated based on the
Trial ID number. A total of 1146 unique clinical trials were used
to create an original database.
To provide a detailed outlook on the use of viral vectors in GM
vaccine trials, the clinical trials database was analysed in a vector
specific way. The progress of vector-based vaccines as a share of
all GM vaccines was examined, as well as the spread of specific
vectors and their prevalence for specific indications. Data entriesTable 3
Patent search.
Database
Espacenet
Search Terms
Medicinal preparations 
containing antigens or 
antibodies (A61K39/xx) 
AND vaccin*
Medicinal preparations 
containing genetic material 
which is inserted into cells 
of the living body to treat 
genetic diseases; Gene 
therapy (A61K48/xx) AND 
vaccin*
Mutation or genetic 
engineering; DNA or RNA 
concerning genetic 
engineering, vectors, e.g. 
plasmids, or their isolation, 
preparation or purification; 
Use of hosts therefore 
(C12N15/xx) AND Genetic* 
OR Modif*
#Unique
40.3on vector trials were sorted by their indication and frequency,
and the 10 most prevalent indications were selected to form a
new data subset. This subset was analysed on the specific types
of vectors used per indication, and a comparison was made for
these indications with the complete dataset of all GM vaccines.
The results are shown in Table 7.
2.4. Search for registered GM and non-GM vaccines
Data concerning registered vaccines was obtained from govern-
mental databases of the following regions; USA, EU, Brazil, India,
China, South-Africa, Australia and Japan (Table 5). BRICS countries
were selected (only four out of five BRICS countries were included,
Russia being omitted due to the general inaccessibility of Russian
registers), because of their rapidly growing economies and poten-
tial for the industry. Currently, a total number of 821 registered
human vaccines are on the market. After deduplication, 797 regis-
tered vaccines remained, of which 124 related to GM vaccines.
Boolean search terms used to classify vaccines were: ‘‘Genet⁄”,
‘‘Modif⁄”, ‘‘Engin⁄”, ‘‘DNA/RNA”, ‘‘Recombin⁄”, ‘‘Vector”, ‘‘Chimeric”,
‘‘VLP/Virus-like” and ‘‘Virosome”. In order to analyse the availability
of vector-based vaccines on the market, an analysis was performed
on this database on vaccines classified as vector-based.
2.5. Data convergence
2.5.1. Patents and clinical trials
In order to provide an overview on the prevalence of vectors
that have been patented and/or registered for clinical trials, two
more data analyses were performed. Initially, the comprehensive
patent database, that was created as described above, was analysed
for data on the specific vector types. This data was then combined
with data on vector types from the clinical trial database.
Relevant patent entries were selected from our database based
on the presence of CPC codes related to vectors in the patent appli-
cation and a sub database was created, including 73 different vec-
tors or vector combinations extracted from 10287 unique patents.
As many of these vectors only appeared a few times, the top 21 of Patents
08
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Fig. 1. Predominant CPC codes for GM vector-based vaccine patents. Illustration of the CPC codes present in the patent database for GM vaccines. The figure should be read
from the inside out, starting with the middle circle, each additional layer adds a new subsection to the code of the previous layer. The outer shell consists of the numbers
behind the ‘‘/”, completing the CPC code.
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in 21 different vectors mentioned in 9088 unique patents.
For the clinical trials analysis, a similar procedure was applied.
Instead of searching for CPC codes, data on the technology class of
the vaccine was extracted from the previously generated clinical
trial database by searching the variable ‘‘Expression System”. Rele-
vant data on vectors was extracted, resulting in 17 vectors in 117
phase 1 trials, 14 vectors in 66 phase 2 trials and 2 vectors in 2
phase 3 trials. The results of these analyses are shown in Fig. 3.2.5.2. Evolution of GM vaccines: convergence of all three data bases
In order to visualise the progress of GM vaccines over the years,
a timeline was created using data from all available databases
(patents, clinical trials, and registered) on the prevalence per indi-
cation per year. 16 Indications were selected based on their pres-
ence in all databases, and six indications were selected that were
present in patents and clinical trials, albeit absent in registered.
This resulted in a timeline of vaccine presence per year for 22 indi-
cations spanning from 1976 to 2013. Data on registered vaccines
from India have been omitted from this analysis, as no information
on the dates of application was given in Indian registers. Patents
and clinical trials databases comprise of only GM vaccines. The reg-
istered database has been used in its entirety, both GM and non-
GM vaccines. This visualisation is shown in Fig. 4.3. Results
3.1. Analysing the market
Table 6 provides information on the most frequently used vec-
tors, as mentioned in literature. In total 21 viral, 3 bacterial and 1
plasmid DNA vectors are presented in this table, covering the most
essential vectors of each type for vaccine production or delivery.
This table shows data on several upcoming vectors, which are
being researched, e.g. new subtypes of poxviruses, adenoviruses,
and novel bacterial vectors. Furthermore, the table comprises indi-
cations mentioned for these vectors, their advantages and chal-
lenges. The viral vector part covers general viral vector species,
and several important main viral families followed by their rele-
vant species. At this point, viral vectors have been researched in
more detail than bacterial vectors. Poxviruses and adenoviruses
are most frequently mentioned in literature. Moreover, details on
the application of these two viral families and several of their spe-
cies and subspecies, as vectors for vaccine development, are more
common.
Fig. 1 shows the most prevalent CPC codes in vector-based vac-
cine research. The most prevalent patent precursors are ‘‘Vectors or
expression systems specially adapted for eukaryotic hosts - note: This
group covers the use of eukaryotes as hosts” (C12N15/79) with 8216
patent entries, ‘‘Virus: expressing foreign proteins” (A61K2039/5256)
Table 4
Clinical Trials search.
Database Search terms Variables
WHO International Clinical Trials Registry Platform ‘‘Attenuated NOT Live-attenuated” ‘‘Development phase”
‘‘Chimeric” (1, 2, or 3)
‘‘DNA”
‘‘Engineered” ‘‘Expression system”
‘‘Genetic”
‘‘Genetically Engineered” ‘‘Indication”
‘‘Genetically Modified”
‘‘Live” ‘‘Production system”
‘‘Live-attenuated”
‘‘Modified” ‘‘Specific target”
‘‘Recombinant Protein”
‘‘Recombinant” ‘‘Technology Class”
‘‘RNA”
‘‘Vector”
‘‘Virosome” ‘‘Type of Organism”
‘‘VLP”
Total number of vaccines after deduplication 1146
Of which GM vaccines 762
Of which vector-based GM vaccines 226
Table 5
Registered database search.
Region Database Results Reference
US US Food and Drug Administration (FDA) 100 [17]
EU European Medicines Agency (EMA) 41 [18]
Brazil Oswaldo Cruz Foundation (Fiocruz) 9 [19]
India Central Drugs standard control
organisation (CDSCO), Medguide India
218 [20,21]
China China Food and Drug Administration
(CFDA)
317 [22]
South
Africa
South African Vaccination and
Immunisation Centre (SAVIC)
37 [23]
Australia Government Department of Health,
Register of Therapeutic Goods
75 [24]
Japan Pharmaceuticals and Medical Devices
Agency (PMDA)
24 [25]
Total results 821
Total results after deduplication 797
Of which GM vaccines 124
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expressing foreign proteins” (A61K2039/523) with 1813 entries,
respectively.
Notable prevalent viral vectors are ‘‘Orthopoxvirus, vaccinia/-
variola” (C12N2710/24141, 2200 entries), ‘‘Mastadenovirus”
(C12N2710/10341, 1549 entries), ‘‘Nucleopolyhedrovirus”
(C12N2710/14141, 1050 entries) and ‘‘Poxviridae”
(C12N2710/24041, 744 entries).
As demonstrated in Table 7, analysing clinical trials in detail
shows that out of 762 GM vaccine trials, 198 are vector-based. This
corresponds to a percentage of 26%. Indications with a high per-
centage for vector-based GM vaccine trials are variola (89%),
epstein-barr (67%), HIV (56%), tuberculosis (TB) (42%), cancer
(38%), and malaria (38%). Indications that have very little vector-
based trials are influenza (3%), human papillomavirus (HPV) (1%),
and hepatitis B (1%). The most prominent vectors are the vaccinia
virus (modified vaccinia Ankara (MVA) & New York strain (NYVAC),
36.3%) and adenoviruses (17.7%).
The cumulative frequency of the aforementioned vectors per
year is shown in Fig. 2. Results from this graph and table illustrate
a significant increase in MVA and adenovirus application over the
years, while growth of vaccines based on vaccinia virus, ALVAC,
and fowlpox virus has stagnated.
The results from our registered vaccines search show that the
first vector-based vaccine registered for use on the market is IMO-JEV (2010), a Japanese Encephalitis vaccine, based on a yellow fever
virus (family Flaviviridae) vector [61]. The second is the tetravalent
dengue vaccine, Dengvaxia (2015) comprising a Yellow Fever virus
(YFV) encoding two JE viral proteins [62].3.1.1. Data convergence
The analysis of the prevalence of specific vectors in patents and
clinical trials is presented in Fig. 3. A total of 9088 vector-based
vaccine patents were evaluated for the patent database. The ortho-
poxvirus (vaccinia/variola) is most prevalent with 2200 occur-
rences, followed by the mastadenovirus with 1549 entries. Other
frequent vectors were the nucleopolyhedrovirus (1050 entries),
poxviridae (744), and HIV (407). For clinical trials, a different, less
diverse set of vectors was obtained. In Phase 1, MVA is most preva-
lent, 37 out of 117 trials. Other frequently present vectors are ade-
novirus (25), vaccinia virus (21), and ALVAC (9). For Phase 2, MVA
is again prevalent with 14 out of 66 trials. Other vectors include
adenovirus (10) and fowlpox-vaccinia combination (10). In phase
3 the use of ALVAC and allogeneic cells are present once each.
The convergence of all databases is presented in Fig. 4. This fig-
ure illustrates patent applications and clinical trials for the indica-
tions cancer and HIV over the years, yet with plenty of results yet
very little success (one registered vaccine for cancer, bladder carci-
noma, in 2009) [63]. For indications like Haemophilus influenzae
(Hib) infection, hepatitis A (Hep A), Japanese encephalitis (JEV),
and meningococcus, several vaccines have been registered in the
past 20 years. Less patents and clinical trials are present for these
indications, compared to HIV and cancer. Influenza has a signifi-
cant amount of both registered vaccines and clinical trials.4. Discussion
This study provides an overview of the vector-based GM vac-
cine pipeline and market, indicating that poxviruses and aden-
oviruses are among the most prominent vectors in GM vaccine
development. Our findings show that vector-based vaccines com-
prise a significant part of all GM vaccines (26%) in the pipeline.
To realise data completeness, four different stages of research
were conducted and analysed in detail. These stages covered liter-
ature, patents, clinical trials, and the registered market of vector-
based GM vaccines, generating an idea of evolution these vaccines
have gone through over the years. During the start of this project it
became clear that GM vaccines have no unambiguous definition.
Table 6
Main types of vectors for GM vaccine application. Summary of properties of various vectors, the indications they are associated with and their advantages and disadvantages, as
retrieved from literature. In bold the important families of viral vectors are shown, below these, in regular font, the subsequent species. Abbreviations: HCV: Hepatitis C virus,
HIV: Human immunodeficiency virus, hMPV: Human metapneumovirus, hPIV: Human parainfluenzavirus, HPV: Human Papillomavirus, JEV: Japanese encephalitis virus, MERS:
Middle east respiratory syndrome, NDV: Newcastle disease virus, NOS: not otherwise specified, RSV: Respiratory syncytial virus, SARS: Severe acute respiratory syndrome, SFV:
Semliki forest virus, SIN: Sindbis virus, SIV: Simian immunodeficiency virus, TB: Tuberculosis, VEE: Venezuelan Equine encephalitis virus.
Vectors Possible
indications (CT,
Pre-CT, in vitro)
Advantages Challenges Ref.
Nucleic acids
Plasmid DNA – Infectious dis-
eases (NOS)
– Influenza
– Easy production and low costs
– Stable (genetically, shelf life)
– Production is independent of classical
production technology
– Induces both humoral and cellular
immune response
– No interferencebypre-existing immunity
– Safer compared to viruses
– Low immunogenicity
– Requires dose increases, multiple
doses or adjuvants
– Risk of integration of vaccine
DNA in host genome
– Risk of tolerance induction
[3,9,26–29]
Viruses
Adeno associated virus (AAV) – Cedar virus
infection
– Hendra virus
infection
– HIV infection
– HPV infection
– Influenza
– Nipah virus
infection
– Infects a wide range of tissues
– Induces both humoral and cellular
immune response
– Non-pathogenic
– Unable to replicate in normal human
cells
– Expresses transgenes at a high and sus-
tained level
– Several serotypes available, avoids pre-
existing immunity
– Flexible modification of viral genes
possible
– Pre-existing immunity
– Low titer production
– High production costs
– Limited transgene capacity
– Lack of CD8+ T cell responses
with natural AAV serotypes
– Low immunogenicity compared
to other viral vectors (Ad)
[9,28,30–32]
Yellow Fever virus – Yellow Fever
virus infection
– Japanese
Encephalitis
– Dengue
– West Nile
virus infection
– Only vector-based vaccine on the mar-
ket so far
– Easy production and low costs
– Single dose effective
– Absence of tropism
– No pre-existing immunity in non-
endemic areas (North America,
Eurasia)
– Pre-existing immunity in ende-
mic areas (South America, Africa)
– Risk of YFV associated viscero-
tropism
[33,34]
Adenoviruses – Anthrax
– Cancer
– Ebola
– Hepatitis B
– HIV infection
– Influenza
– Malaria
– Measles
– Plague
– Rabies
– SARS
– TB
– Easy production and low costs
– Stable (Thermally, shelf life)
– Infects a wide range of hosts
– Grows at high titers in cell culture
– Can be mutated to render it unable to
replicate in normal human cells
– Can be modified to circumvent pre-
existing immunity
– Can induce both mucosal and systemic
immunity
– Strong T cell effector memory, little T
cell central memory responses (Suita-
ble for priming)
– Several serotypes available
– Pre-existing Immunity
– Risk integration of vaccine DNA
in host genome
– Rapid elimination of transduced
cells in vivo
– Human adenoviruses are onco-
genic in animals
[9,11,26–
28,30,32,35–42]
Human serotypes (Ad4, Ad26, Ad35) – Considerably less pre-existing immu-
nity than regular serotype Ad
– Grows at high titers in cell culture
– Cross-reactivity after
immunisation
[42,43]
Simian serotypes (ChAd63, ChAdOx1) – Ebola
– Hepatitis C
– Malaria
– Low pre-existing immunity in humans
– Highly immunogenic
– Can be mutated to be unable to repli-
cate in normal human cells
– Requires booster for high T-cell
response
[40,43–45]
Alphaviruses – Cancer
– Ebola
– Hendra virus
infection
– HIV infection
– hPIV infection
– HPV infection
– Influenza
– Malaria
– Marburg virus
infection
– Nipah virus
infection
– SFV infection
– SIN
– TB
– VEE
– High expression capacity
– Can infect dendritic cells
– Induces apoptosis in infected cells
– Absence of pre-existing immunity in
humans
– RNA virus, unable to integrate in host
genome
– Cytotoxicity
– Difficult production
– High production costs
– Possibly instable
– Relatively unexplored in humans
– Small to moderate foreign anti-
gen load
[9,27,28,35,38,46]
(continued on next page)
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Table 6 (continued)
Vectors Possible
indications (CT,
Pre-CT, in vitro)
Advantages Challenges Ref.
Semliki Forest virus – Cancer
– Chikungunya
virus infection
– Induces both humoral and cellular
immune response
– High expression capacity
– Absence of pre-existing immunity in
humans
– RNA virus, unable to integrate in host
genome
– Encapsulated particles prevent vector
specific immunity due to repeated use
– Biosafety issues
– Instable genome
[46]
Sindbis virus – Absence of pre-existing immunity in
humans
– RNA virus, unable to integrate in host
genome
– Biosafety issues
– Instable genome
[46]
Venezuelan Equine Encephalitis virus – Cancer – Induces both humoral and cellular
immune response
– Can induce both mucosal and systemic
immunity
– Absence of pre-existing immunity in
humans
– RNA virus, unable to integrate in host
genome
– Biosafety issues
– Instable genome
[46]
Nonsegmented Negative-sense ssRNA
viruses
– Influenza – Simple well known genomes
– Stable genome compared to psRNA
– Grown in high titers in many cell lines
– Can induce both mucosal and systemic
immunity
– Able to carry large and multiple inserts
while maintaining a relatively small
genome
– Gradient gene expression
– Instable genome [38]
Measles virus – HIV infection
– Measles/HIV
combination
– West Nile
virus infection
– RNA virus, unable to integrate in host
genome
– Well known homologous vaccine
– Can induce both mucosal and systemic
immunity
– Pre-existing immunity
– Moderate foreign antigenic load
[9,28,38]
Newcastle disease virus/avulavirus – Avian
influenza
– Cancer
– Ebola
– Influenza
– NDV infection
– RSV infection
– SARS
– SIV infection
– Can be grown in either eggs or cell
culture
– Grows at high titers in Vero cells
– Bivalent vaccine for influenza and NDV
for poultry
– Intranasal or pulmonary delivery
possible
– No pre-existing immunity
– Administration both mucosal surfaces
of respiratory and alimentary tracts
– Needle free administration possible
– Risk of tolerance induction
– Instable genome
[27,38]
Para Influenza Virus 5 (PIV5) – Influenza
– Vaccinia
– Non virulent
– Infects a wide range of cell types
– Grows high titers in Vero cells
– Gradient gene expression
– Flexible modification of viral genes
possible
– Administration both intranasally and
intramuscularly
– No pre-existing immunity
– No clinical safety data for use in
humans available
[38,47]
Sendai virus – High immunogenicity [32]
Vesicular Stomatitis virus – Ebola
– Filovirus
infections
– Hantavirus
infection
– Hepatitis B
– Hepatitis C
– HIV infection
– HPV infection
– Influenza
– RSV infection
– TB
– Low seroprevalence in humans
– Infects a wide range of tissues and hosts
– Stimulates a strong interferon response
– Potential to protect against subtypes of avian influenza in poultry
– High expression levels of inserted genes
– Low pre-existing immunity
[9,27,28,38]
Poxviruses – HIV infection
– Malaria
– Rabies
– TB
– Easy production and low costs
– Stable (genetically, shelf life)
– Broad tropism for mammalian cells
– Induces both humoral and cellular
immune response
– Pre-existing immunity
– Biosafety issues
– Competition for antigen presen-
tation pathways
[9,27,28,30,38,48–
51]
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Table 6 (continued)
Vectors Possible
indications (CT,
Pre-CT, in vitro)
Advantages Challenges Ref.
– Cytoplasmic site of gene expression
– Able to carry large and multiple DNA
inserts
– Rapid elimination of transduced
cells in vivo
– Tropism
ALVAC (Canarypox) – Avian
influenza
– Fowlpox
– Influenza
– HIV infection
– Induces both humoral and cellular
immune response
– Stable (genetically, shelf life)
– Unable to replicate in mammalian cells
– No pre-existing immunity
– Can induce strong CD8+ T cell
immunity
– Low efficacy [26,39,50,52]
NYVAC (Vaccinia) – Cancer
– HIV infection
– Influenza
– Japanese
Encephalitis
– Malaria
– Rabies
(animal)
– Smallpox
– Stable (thermally, genetically, shelf
life)
– Reduced ability to replicate in human
cells
– High level of safety and gene expres-
sion/immune response
– Can induce both mucosal and systemic
immunity
– Induces a delayed antiviral response
– Able to carry large and multiple DNA
inserts
– Pre-existing immunity [28,39,49]
Modified Vaccinia Ankara (MVA) – Cancer
– Coronavirus
infections
(SARS, MERS)
– Hepatitis C
– HIV infection
– hMPV
infection
– hPIV infection
– Influenza
– Malaria
– RSV infection
– Smallpox
– TB
– Stable (thermally, genetically, shelf
life)
– Induces both humoral and cellular
immune responses
– Unable to replicate in mammalian cells
– Can induce both mucosal and systemic
immunity
– Induces both CD4+ and CD8+ T cell
responses
– Induces strong CD8+ T cell central
memory over effector memory (Suita-
ble for booster)
– Can encode one or more foreign anti-
gens (multivalent vaccine)
– Intrinsic adjuvant capacities
– Rapid clearance
– Fast construction of recombinant MVA
(6-12wks)
– Little pre-existing immunity
– Limited priming capacity
– Vector specific immunity on
repeated use
[11,26–
28,32,38,39,48–
50,53–56]
Retroviruses – Long term gene expression – Generation of replication-com-
petent virus
– Infects dividing cells only
[32]
Lentivirus – Long term gene expression
– Infects non-dividing and dividing cells
– High immunogenicity
– Generation of replication-com-
petent virus
– Potential for tumorigenesis
[32,57]
Bacteria
Lactic Acid Bacteria (Lactococcus,
streptococcus, pediococcus,
leuconostoc, lactobacillus)
– Autoimmune
diseases
– Naturally present in host
– Much safer than traditional attenuated
vaccines in children and immunocom-
promised people
– History in food industry, recognised as
safe
– Probiotics, have health promoting
properties
– Capacity to survive the gastrointestinal
tract
– Mucosal administration could reduce
traditional side effects
– Limited knowledge available for
use as vector vaccine compared
to viral vectors
[39,58]
Listeria – Cancer – Induces both CD4+ and CD8+ T cell
responses
– Naturally present in host
– Pre-existing immunity can lead to
stronger immune response
– Much safer than traditional attenuated
vaccines in children and immunocom-
promised people
– Induce robust T-cell immune response
– Can invade a variety of cells, including
antigen presenting cells
– Can reside in the cytoplasm
– Limited knowledge available for
use as vector vaccine compared
to viral vectors
[39,59]
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Table 6 (continued)
Vectors Possible
indications (CT,
Pre-CT, in vitro)
Advantages Challenges Ref.
Salmonella – Salmonellosis
(in animals)
– Typhoid fever
– HIV infection
– Naturally present in host
– Pre-existing immunity can lead to
stronger immune response
– Much safer than traditional attenuated
vaccines in children and immunocom-
promised people
– Induces robust T-cell immune response
– Induces both humoral and cellular
immune responses
– Can induce both mucosal and systemic
immunity
– Able to carry large DNA inserts
– Pre-existing immunity could still
be a limiting factor
– Limited knowledge available for
use as vector vaccine
[9,39,60]
Table 7
Use of viral vectors in GM vaccine Clinical Trials. Types of vectors that are being used for specific indications (top 10 vector vaccine indications) in GM vaccine trials, and a
comparison of vector-based vaccine GM trials compared to all GM vaccine trials.
Indication All GM vaccine trials (n) Vector-based vaccines
(n)
(%) Type of vector
Adenovirus Vaccinia (MVA & NYVAC) Fowlpox ALVAC Fowlpox &
vaccinia
Other
Cancer 208 78 38 11 11 12 6 14 24
Influenza 157 5 3 1 3 0 0 0 1
HIV 153 86 56 25 43 3 11 0 4
HPV 105 1 1 0 1 0 0 0 0
Hepatitis B 82 1 1 0 1 0 0 0 0
Malaria 29 11 38 2 8 0 0 0 1
Ebola 4 1 25 1 0 0 0 0 0
Variola 9 8 89 0 8 0 0 0 0
TB 12 5 42 0 5 0 0 0 0
Epstein-
Barr
3 2 67 0 2 0 0 0 0
Total 762 198 26 40 82 15 17 14 30
Bold/italic values represent indications with a high percentage for vector-based GM vaccine trials.
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Fig. 2. Cumulative frequency of vectors in clinical trials. Supporting figure for Table 2, showing the cumulative frequency of the various vectors used from 1999 until 2013.
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104 Respirovirus
113 Morbillivirus
128 Pneumovirus
139 Influenzavirus B
142 Gammaretrovirus
154 Dependovirus
166 Vesiculovirus
177 Lentivirus
180 Avulavirus
183 Herpesviridae
215 Baculoviridae
229 Adenoviridae
257 Simplexvirus
292 Mardivirus
326 Influenzavirus A
333 Varicellovirus
407 HIV
744 Poxviridae
Nucleopolyhedrovirus 1050
Mastadenovirus 1549 
Orthopoxvirus 
(Vaccinia & Variola) 2200 
Patents Database (9088) Clinical Trials Phase 1 (117) Clinical Trials Phase 2 (66) Clinical Trials Phase 3 (2) Registered (1)
1 Salmonella Typhi 
1 Listeria
1 MDV
1 Fowlpox & Lymphocytes
1 Hepatitis B
1 Dendritic cells & Adenovirus
2 Autologous cells
2 Allogeneic cells
1 Adenovirus & Autologous tumor cells
1 AAV
3 Fowlpox & Vaccinia
3 Measles virus
7 Fowlpox
9 ALVAC
25 Vaccinia
Adenovirus 25
MVA 37 
1 Fowlpox & Lymphocytes
1 Lymphocytes
1 Allogeneic cells
1 AAV
2 ALVAC & Lymphocytes
3 Dendritic cells & Adenovirus
4 Vaccinia
 5 ALVAC
6 Fowlpox
7 Autologous tumor cells 10 Fowlpox & Vaccinia
Adenovirus  10
MVA 14
Allogeneic cells 1
Yellow fever virus 1
1 ALVAC
Fig. 3. Prevalence of vectors used in Patents and Clinical Trial phases for GM vaccines The illustration indicates the prevalence of various vectors used for GM vaccines for
each phase of research. Each pie chart represents the contribution of each individual vector to the total amount of vectors in the specific database (Patents, CT1, CT2, CT3).
Abbreviations: HIV: Human immunodeficiency virus, AAV: Adeno associated virus, ALVAC: Canarypox virus, MVA: modified vaccinia Ankara.
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Fig. 4. Evolutionary timeline of indications and prevalence generated from various databases. The motion of indications through time in three different phases of research
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RSV: Respiratory Syncytial virus. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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vaccines, nevertheless these terms were all used in an inconsistent
manner. The definition of GM vaccines was narrowed down by
delineation of search terms found in CPC codes and literature.
Literature widely acknowledged that, compared to bacterial or
DNA vectors, viral vectors have been researched in more detail
(Table 6). Poxviruses and adenoviruses are referenced often and a
lot of details are provided on the use of these families as viral vec-
tors. Nevertheless, pre-existing immunity is still a major obstacle
for several viral vectors (Table 6). This is of special concern forthe use of adenovirus vectors, although several strategies to cir-
cumvent this problem have been developed [40,44,45,64]. Interest-
ingly there are many data suggesting that this seems to be les of a
problem for MVA based vaccine candidates [65–67].
In comparison with viral vectors, DNA and bacterial vectors
show potential in this respect, but this require more research. Fur-
thermore there are several other limitations to overcome. The pri-
mary limitation of bacterial vectors is their lack of immunogenicity
compared with viral vectors [68]. In addition, viruses are relatively
easier to work with, since they have less complex genome than
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tioned in literature (e.g. Escherichia coli, Vibrio cholerae, Mycobacte-
ria, and Shigella spp.), these are not mentioned in the table due to
lack of sufficient information on their advantages and disadvan-
tages [39].
The results of the patent search show that the most prominent
CPC codes in the patent database on vector-based vaccines cover
general information on vectors (C12N15/79, A61K2039/5256,
A61K2039/523). These CPC codes do not comprise specific vectors
but are general indicators for vector-based vaccines. A large variety
of different vector types are being patented for vaccine develop-
ment (Fig. 1). According to the patent database, both ‘‘mastaden-
ovirus” and ‘‘orthopoxvirus: vaccinia/variola” are the most
prominent vectors. Human adenoviruses are part of mastaden-
ovirus genus, which in turn is a large genus of the adenoviridae
family. It is notable that orthopoxvirus: vaccinia/variola as well
as poxviridae appear in the patent results. The species vaccinia
virus and variola virus are part of the genus orthopoxvirus, which
belongs to the family of Poxviridae. The explanation behind this
seemingly double occurrence is that CPC codes for both the species
and the family are present in Espacenet. There is one CPC code for
both vaccinia and variola combined, rather than a separate code for
each of these species.
For clinical trials, vector-based vaccines play quite an important
part in GM vaccine trials as a whole. 26% of all GM vaccine trials
use vector-based candidate vaccines, especially for currently unde-
feated indications, such as cancer, HIV, TB, and malaria (Table 7).
Although no active clinical trials on malaria based on fowlpox vec-
tors are provided in the clinical trials database (clinicaltrial.gov),
literature shows that fowlpox vectors are being examined in com-
bination with different vaccination regimens [70,71]. Intervention
strategies for these diseases represent a large unmet medical need,
still causing over a million deaths every year [72]. With limited if
any cure available, new methods might provide additional value
to vaccine research and development, in hope for a breakthrough.
This premise is confirmed by Fig. 4. Cancer, HIV, and malaria show
a large presence in both patent and clinical trial databases, while
Hib, Hepatitis A, and meningococcus show little development in
patent and clinical trials stages in recent years. This implies a lower
need for new vaccine technologies for these indications, as current
vaccines based on conventional methods are apparently suffi-
ciently satisfactory [73–75]. Table 7 also shows that very little
vector-based vaccine trials are present for more or less treatable
diseases such as HPV induced neoplasias, hepatitis B, and influen-
za. Apparently there is less medical need for vector-based vaccines
for these indications, as vaccine candidates are available based on
GM-based and non-GM-based techniques [76–78]. There is, a sig-
nificant amount of active non-vector-based GM trials for these
three indications, demonstrating the variety of GM techniques
applied in vaccine development. For influenza and hepatitis B vac-
cine production, the use of recombinant DNA technology is already
common practice [6,79]. Therefore, the focus of research is on opti-
mising the technology used, rather than on investing in new
vector-based technology research.
The increase in MVA vector usage compared to the use of vac-
cinia virus indicates that MVA has started to replace regular vac-
cinia virus in vector-based vaccine development, as vaccinia
trials have stagnated while MVA trials are increasing rapidly
(Fig. 2). The reasons for this replacement is predominantly related
to the safety and efficacy of MVA, as it only causes an abortive
infection, while inducing an abundant expression of the target
immunogen, leading to impressive protective immune responses
[12]. The prominent use of adenoviruses as viral vectors is proba-
bly due to the considerable knowledge on this virus family, the
ease of manipulation of the virus for use in vector-based vaccines,
and the broad tissue tropism associated with this virus [40,80].The consensus that both poxviruses and adenoviruses are
important for vector-based GM vaccine research is also strength-
ened by data shown in Fig. 3, indicating high prevalence of these
vectors in both patents and clinical trials. For patents and the first
two phases of clinical trials, both orthopoxviruses vaccinia virus
(mentioned in combination with variola virus), and adenoviruses
are well represented (though in patents adenoviruses are not men-
tioned directly, these are part of the Mastadenovirus genus).
While analysing this data set, it is important to keep in mind
that the data bases used are snapshots of each phase of research
and development pipeline. Patents are made public 18 months
after submission, but when patents are retracted before this
18 months period, they disappear from Espacenet. Clinical trials
only show active and on-going trials (hence the database starts
in 1999). Discontinued or terminated trials are removed from the
database, consequently, making direct correlations between data-
bases unjustifiable. Therefore, the analyses conducted in this study
are not directly between databases but each database is seen as an
individual snapshot.
Even though numerous vectors are being studied in different
phases of pre-clinical and clinical research, the presence of their
majority in phase 1 indicates that the evolution of vector-based
vaccines has only just begun. The large amount of vector types
being patented, or having reached phase 1 clinical trials, show a
lot of promise, as new techniques might lead to a new generation
of safer, more efficient, and cost-effective vaccines.
Comparing the data presented with the literature study we con-
ducted initially, it seems that a lot of new vectors are being
patented while little published information is available. This could
indicate that some vectors are being patented beforehand, not nec-
essarily in order to start a new study, but in case a method or tech-
nique is developed to make them suitable for vaccine production.
Without patents, anyone could start developing these vectors
without legal consequences, leading to companies competing to
sell the vaccine for the lowest price possible. When revenues from
vaccine sales eventually do not lead to return on investment for
past and future research and development there would be no
incentive for the development of new generations of vaccines.
Therefore the use of a patent search was considered a valid and
valuable approach to gather part of our dataset.
In conclusion, our data suggest that although currently there
are two licensed, vector-based human vaccine on the market and
that this field is still in its early days, vector-based vaccines may
offer a cost-effective alternative for the production of safe and
effective vaccines against diseases for which no or less perfect vac-
cines exist today. The most promising vectors for vaccine develop-
ment at this moment appear to be poxvirus and adenovirus
vectors. This may be concluded for their abundant use in the devel-
opment of vaccines against diseases like HIV-AIDS, malaria, tuber-
culosis and different forms of neoplastic disease. It may be
expected that the current efforts spent on developing vector-
based vaccines, may lead to promising vaccine candidates for these
indications and therefore hold promise for current and future
unmet medical needs. Therefore, after the recent eradication of
smallpox using Jenner’s vaccinia virus as the first vaccine, this
and other viruses may now be the basis for constructing vectors
that may help us control other major scourges of mankind.
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